M.D. from Harvard Medical School. Dr. McDonoughs qualifications to sit on our Board of Directors include his valuable experience as an M.D. and the CEO of a rare disease company, Sobi, as
well as his prior experience at Genzyme, one of the worlds largest biopharmaceutical companies, in addition to his experience on the board of directors of a publicly traded company.
Robert J. Perez.
Mr. Perez has served as a member of our Board of Directors since September 2015. He is the founder and Managing
Partner of Vineyard Sound Advisors, a biopharmaceutical advisory firm, and the Executive Chairman at Akili Interactive Labs, Inc., a private digital therapeutics company. He is the former Chief Executive Officer of Cubist Pharmaceuticals, Inc., a
public pharmaceutical development company, which was acquired by Merck in January 2015. He joined Cubist in August 2003 as Senior Vice President, Sales and Marketing, and led the launch of
Cubicin
®
(daptomycin for injection). He served as Executive Vice President and Chief Operating Officer from August 2007 to July 2012 and President and Chief Operating Officer from July 2012 to
December 2014. Prior to joining Cubist, he served as Vice President of Biogen, Inc.s CNS business unit from 2001 to 2003, where he was responsible for commercial leadership of an $800 million neurology business unit, and from 1995 to 2001
he held positions of increasing responsibility within Biogens CNS commercial organization. From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez currently serves as a member of
the board of directors of public companies Unum Therapeutics Inc., AMAG Pharmaceuticals, Inc., Cidara Therapeutics, Inc., and Spark Therapeutics, Inc., and private companies Vir Bio, and Akili Interactive Labs. Mr. Perez is the Founder and
Chairman of Life Sciences Cares since January 2016, and has also been a member of the Board of Trustees at The Dana Farber Cancer Institute, Inc. since January 2013. Mr. Perez received a B.S. in business from California State University, Los
Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles. Mr. Perezs qualifications to sit on our Board of Directors include his valuable pharmaceutical experience, including his
service at Cubist Pharmaceuticals, Inc., a commercial stage biotechnology company, in addition to his experience at Biogen, Inc., and his experience as a director in many growth companies in the biotech sector.
Peter Barrett, Ph.D.
Dr. Barrett has served as the Chairman of our Board of Directors since August 2006. Dr. Barrett joined
Atlas Venture, an early-stage venture capital fund, in 2002, and currently serves as a partner in the life sciences group. Previously, from 1998 to 2002, he was a
co-founder,
executive vice president and chief
business officer of Celera Genomics. Prior to Celera, from 1979 to 1998, Dr. Barrett held senior management positions at Perkin-Elmer Corporation, most recently serving as vice president, corporate planning and business development.
Dr. Barrett served on the boards of directors of SciClone Pharmaceuticals, Inc. from 2011 to 2013, and Helicos BioSciences Corporation from 2003 to 2012 and Vitae Pharmaceuticals, Inc. from 2014 to 2015. Dr. Barrett currently serves on the
boards of directors of the Perkin-Elmer Corporation and Synlogic, Inc., and several other privately held companies. Dr. Barrett is a Senior Fellow at Harvard Business School and is the faculty chair of the key advisory board of the Blavatnik
Fellowship Program. He is a member of the research council at Boston Childrens Hospital. Dr. Barrett holds a B.S. in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and a Ph.D. in
analytical chemistry from Northeastern University. He also completed Harvard Business Schools Management Development Program. Dr. Barretts qualifications to sit on our Board of Directors include his extensive leadership, executive,
managerial and business experience with life sciences companies, including experience in the formation, development and business strategy of multiple
start-up
companies in the life sciences sector.
Bruce Booth, Ph.D.
Dr. Booth has served as a member of our Board of Directors since August 2006. Dr. Booth joined Atlas
Venture in 2005, and currently serves as partner. Prior to joining Atlas Venture, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm. Prior to Caxton, from 1999 to 2004,
Dr. Booth was an associate principal at McKinsey & Company, a global strategic management consulting firm. Dr. Booth serves on the board of Unum Therapeutics Inc. and miRagen Therapeutics, Inc., publicly-traded companies, and
several privately-held companies. Dr. Booth earned a Ph.D. in molecular immunology from Oxford Universitys Nuffield Department of Medicine and a B.S. in biochemistry from Pennsylvania State University. Dr. Booths qualifications
to sit on our Board of Directors include his
6